Osimertinib received accelerated approval by the US Food and Drug Administration (FDA) in November 2015 and was conventionally approved in March 2017 for the treatment of metastatic EGFR T790M mutation-positive NSCLC in patients who have disease progression during or after EGFR-TKI therapy, which was currently the first effective marketed drug targeting the T790M resistance mutation (Osimertinib (TAGRISSO), 2017). Here, EGFR is linked to non-small cell lung carcinoma.